Recombinant activated factor VII
Factor VIIa (recombinant)
Brand names: NovoSeven
Adult dose
Dose: Haemophilia with inhibitors: 90 micrograms/kg IV every 2–3h until haemostasis. Acquired haemophilia / Glanzmann's: per protocol
Route: IV bolus
Frequency: q2-3h
Clinical pearls
- Haemophilia A/B with inhibitors, acquired haemophilia, congenital factor VII deficiency, Glanzmann's
- Off-label massive haemorrhage use should follow local major-haemorrhage protocol with specialist input
Contraindications
- Hypersensitivity to mouse/hamster/bovine protein
Side effects
- Thromboembolism
- Hypersensitivity
- Pyrexia
Interactions
- Avoid concomitant prothrombin complex concentrates
Monitoring
- Coagulation
- Clinical haemostasis
Reference: BNF; UKHCDO; NICE evidence summary; https://bnf.nice.org.uk/drugs/factor-viia/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO